Literature DB >> 31659791

Parent of origin differences in psychosocial burden and approach to BRCA risk management.

Sharlene Hesse-Biber1, Andrew A Dwyer2, Shiya Yi3.   

Abstract

We conducted a mixed-method study to examine coping response in BRCAwomen based on parent of origin (maternally vs paternally inherited BRCA mutation). Quantitative findings (n = 408) revealed paternally inherited cases had genetic testing later and were more likely to have a cancer diagnosis. Having a maternally inherited mutation was the strongest predictor of proactive risk management response. Qualitative interviews (n = 56) identified proactive responses among maternally inherited cases compared to reactive responses in paternally inherited cases. Findings underscore the importance of unbiased pedigree analysis to determine cancer risk. Women with paternally inherited BRCA mutations may benefit from additional psychosocial support.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRCA mutation; coping cancer; genetic testing; psychosocial; theory of planned behavior

Mesh:

Year:  2019        PMID: 31659791     DOI: 10.1111/tbj.13633

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  2 in total

1.  Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years.

Authors:  Carla Pedrazzani; Chang Ming; Nicole Bürki; Maria Caiata-Zufferey; Pierre O Chappuis; Debra Duquette; Karl Heinimann; Viola Heinzelmann-Schwarz; Rossella Graffeo-Galbiati; Sofia D Merajver; Kara J Milliron; Christian Monnerat; Olivia Pagani; Manuela Rabaglio; Maria C Katapodi
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

2.  Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.

Authors:  Sharlene Hesse-Biber; Memnun Seven; Jing Jiang; Sara Van Schaik; Andrew A Dwyer
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.